Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug containing oryz-aspergillus enzyme (a fungal-derived digestive enzyme blend), pancreatin (a mixture of pancreatic enzymes including amylase, lipase, and protease), and ursodeoxycholic acid (a bile acid). The combination is designed to aid digestion in patients with reduced digestive capacity due to conditions such as dyspepsia, malnutrition associated with cirrhosis, or other gastrointestinal disorders. Oryz-aspergillus enzymes help break down carbohydrates and proteins; pancreatin supplements endogenous pancreatic enzymes for fat, protein, and carbohydrate digestion; ursodeoxycholic acid improves bile flow and reduces cholesterol absorption by modifying the composition of bile acids. This combination has been studied for improving symptoms in functional dyspepsia and malnutrition related to liver disease[1][3][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oryz-aspergillus enzyme + pancreatin + ursodeoxycholic acid.